Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R.

Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.

PMID:
30630778
2.

Delamanid in the treatment of multidrug-resistant tuberculosis.

Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):33-37. doi: 10.5588/ijtld.16.0125. Review.

PMID:
28240570
3.

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.

Tupasi T, Gupta R, Danilovits M, Cirule A, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Gentry LM, Geiter LJ, Wells CD.

Bull World Health Organ. 2016 Feb 1;94(2):147-52. doi: 10.2471/BLT.15.154997. Epub 2015 Nov 17.

4.

Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.

Gupta R, Geiter LJ, Hafkin J, Wells CD.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1261-2. doi: 10.5588/ijtld.15.0541. No abstract available.

PMID:
26459547
5.

Delamanid for Extensively Drug-Resistant Tuberculosis.

Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H.

N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. No abstract available.

6.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

7.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

8.

Delamanid for multidrug-resistant pulmonary tuberculosis.

Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.

N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.

9.

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.

Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR.

Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54. doi: 10.5588/ijtld.10.0616.

PMID:
21682970
10.

Determining causes of mortality in children enrolled in a vaccine field trial in a rural area in the Western Cape Province of South Africa.

Moyo S, Hawkridge T, Mahomed H, Workman L, Minnies D, Geiter LJ, Verver S, Kibel M, Hussey GD.

J Paediatr Child Health. 2007 Mar;43(3):178-83.

PMID:
17316193
11.

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.

Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ.

Chest. 2001 Mar;119(3):833-7.

PMID:
11243965
12.

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.

Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J.

Am J Respir Crit Care Med. 2000 May;161(5):1572-7.

PMID:
10806157
13.

A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis.

Palmer CS, Miller B, Halpern MT, Geiter LJ.

J Public Health Manag Pract. 1998 May;4(3):1-13.

PMID:
10186738
14.

Can physicians treat tuberculosis? Report on a national survey of physician practices.

Sumartojo EM, Geiter LJ, Miller B, Hale BE.

Am J Public Health. 1997 Dec;87(12):2008-11.

15.

Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.

Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ.

Am J Respir Crit Care Med. 1997 May;155(5):1735-8.

PMID:
9154885
16.

[Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project].

Magdorf K, Arizzi-Rusche AF, Geiter LJ, O'Brien RJ, Wahn U.

Pneumologie. 1994 Oct;48(10):761-4. German.

PMID:
7808991
18.

Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates.

Jereb JA, Burwen DR, Dooley SW, Haas WH, Crawford JT, Geiter LJ, Edmond MB, Dowling JN, Shapiro R, Pasculle AW, et al.

J Infect Dis. 1993 Nov;168(5):1219-24.

PMID:
7901287
19.

The resurgence of tuberculosis: is your laboratory ready?

Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR Jr, Good RC.

J Clin Microbiol. 1993 Apr;31(4):767-70. No abstract available.

20.

The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis.

Villarino ME, Geiter LJ, Simone PM.

Public Health Rep. 1992 Nov-Dec;107(6):616-25.

21.

Usefulness of skin testing with mycobacterial antigens in children with cervical lymphadenopathy.

Huebner RE, Schein MF, Cauthen GM, Geiter LJ, O'Brien RJ.

Pediatr Infect Dis J. 1992 Jun;11(6):450-6.

PMID:
1608681
22.

Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses.

Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ, Good RC, O'Brien RJ.

Am Rev Respir Dis. 1992 May;145(5):1160-6.

PMID:
1586061
23.

Contribution of pyrazinamide to antituberculosis chemotherapy.

Geiter LJ.

J Infect Dis. 1991 Sep;164(3):610. No abstract available.

PMID:
1869849
24.

Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex.

O'Brien RJ, Geiter LJ, Lyle MA.

Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):821-6.

PMID:
2158257
25.
26.

From the Centers for Disease Control. Conference on new approaches for tuberculosis preventive therapy.

Geiter LJ, O'Brien RJ.

J Infect Dis. 1987 Sep;156(3):536-7. No abstract available.

PMID:
3611841
27.
28.

The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey.

O'Brien RJ, Geiter LJ, Snider DE Jr.

Am Rev Respir Dis. 1987 May;135(5):1007-14.

PMID:
3579001
29.

Short-course chemotherapy of pulmonary tuberculosis.

Geiter LJ, O'Brien RJ.

Am Rev Respir Dis. 1987 May;135(5):1215. No abstract available.

PMID:
3555197

Supplemental Content

Loading ...
Support Center